Mira (the consumer brand of Quanovate) sells a home analyzer, urine test strips and a companion app that quantitatively measures fertility hormones (currently LH) using immunofluorescence to provide personalized cycle predictions. The system displays hormone concentrations on-device and sends results via Bluetooth to an app that provides actionable guidance and an optional subscription with doctor access (free at launch). The company plans to update the device to test additional hormones (it is FDA-cleared to detect estrogen, though that won’t be available at launch), is building a doctor portal, and has discussed anonymized data-sharing for research. In clinical testing on 400 patient samples Mira reported 99% accuracy versus lab equipment and holds 18 IP assets covering hardware, software and data. The device is priced at $199 and ships with 10 test strips; it opened pre-orders at Disrupt and will begin shipping in October 2018. Mira is a Pleasanton, Calif.-based, 36-person team and the company was founded in late 2015.

Total raised

$5M

Funding rounds

1

Latest round

Equity

Latest activity

Sep 2018